| Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. | |
| | |
MedLine Citation:
|
PMID: 19429072 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We examined the effects of JP-1302 (a selective alpha2C antagonist), BRL-44408 (a selective alpha2A antagonist) and yohimbine (a non-selective alpha2 antagonist) on haloperidol-induced bradykinesia and catalepsy in mice to elucidate the role of alpha2 adrenoceptor subtypes in modifying extrapyramidal motor disorders. JP-1302 (0.1-1 mg/kg, s.c.) dose-dependently ameliorated haloperidol-induced bradykinesia in the pole-test and reversed the catalepsy time increased by haloperidol. Antibradykinetic and anticataleptic actions of JP-1302 were statistically significant at 0.3 and 1 mg/kg, and these doses did not alter the ambulatory distance, rearing or center-perimeter residence time in the open-field test. BRL-44408 (1-10 mg/kg, s.c.) and yohimbine (0.3-3 mg/kg, i.p.) also ameliorated haloperidol-induced bradykinesia and catalepsy. However, both agents significantly decreased ambulatory distance and rearing in the open-field test, possibly reflecting their anxiogenic actions associated with alpha2A antagonism. The present study shows for the first time that blockade of alpha2C receptors can alleviate antipsychotic-induced extrapyramidal motor disorders without affecting gross behaviors. |
| | |
Authors:
|
Junta Imaki; Yukari Mae; Saki Shimizu; Yukihiro Ohno |
Publication Detail:
|
Type: Journal Article Date: 2009-03-05 |
Journal Detail:
|
Title: Neuroscience letters Volume: 454 ISSN: 0304-3940 ISO Abbreviation: Neurosci. Lett. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-05-11 Completed Date: 2009-08-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600130 Medline TA: Neurosci Lett Country: Ireland |
Other Details:
|
Languages: eng Pagination: 143-7 Citation Subset: IM |
Affiliation:
|
Laboratory of Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acridines
/
therapeutic use Adrenergic alpha-Antagonists / therapeutic use Analysis of Variance Animals Antipsychotic Agents / toxicity Catalepsy / chemically induced, drug therapy* Dose-Response Relationship, Drug Haloperidol / toxicity* Hypokinesia / chemically induced, drug therapy* Imidazoles / therapeutic use Isoindoles / therapeutic use Male Mice Motor Activity / drug effects Piperazines / therapeutic use Receptors, Adrenergic, alpha-2 / antagonists & inhibitors* Yohimbine / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Acridines; 0/Adrenergic alpha-Antagonists; 0/Antipsychotic Agents; 0/Imidazoles; 0/Isoindoles; 0/JP-1302; 0/Piperazines; 0/Receptors, Adrenergic, alpha-2; 118343-19-4/BRL 44408; 146-48-5/Yohimbine; 52-86-8/Haloperidol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Coumarin effects on amino acid levels in mice prefrontal cortex and hippocampus.
Next Document: Time course of adult castration-induced changes in soma size of motoneurons in the rat spinal nucleu...